Literature DB >> 15004189

Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate.

Norihiko Sasaki1, Nobuaki Higashi, Tomohiro Taka, Motowo Nakajima, Tatsuro Irimura.   

Abstract

Extravasation of peripheral blood monocytes through vascular basement membranes requires degradation of extracellular matrix components including heparan sulfate proteoglycans (HSPGs). Heparanase, the heparan sulfate-specific endo-beta-glucuronidase, has previously been shown to be a key enzyme in melanoma invasion, yet its involvement in monocyte extravasation has not been elucidated. We examined a potential regulatory mechanism of heparanase in HSPG degradation and transmigration through basement membranes in leukocyte trafficking using human promonocytic leukemia U937 and THP-1 cells. PMA-treated cells were shown to degrade 35S-sulfated HSPG in endothelial extracellular matrix into fragments of an approximate molecular mass of 5 kDa. This was not found with untreated cells. The gene expression levels of heparanase or the enzyme activity of the amount of cell lysates were no different between untreated and treated cells. Immunocytochemical staining with anti-heparanase mAb revealed pericellular distribution of heparanase in PMA-treated cells but not in untreated cells. Cell surface heparanase capped into a restricted area on PMA-treated cells when they were allowed to adhere. Addition of a chemoattractant fMLP induced polarization of the PMA-treated cells and heparanase redistribution at the leading edge of migration. Therefore a major regulatory process of heparanase activity in the cells seems to be surface expression and capping of the enzyme. Addition of the anti-heparanase Ab significantly inhibited enzymatic activity and transmigration of the PMA-treated cells, suggesting that the cell surface redistribution of heparanase is involved in monocyte extravasation through basement membranes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004189     DOI: 10.4049/jimmunol.172.6.3830

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Expression of heparanase in vascular cells and astrocytes of the mouse brain after focal cerebral ischemia.

Authors:  Jimei Li; Jin-Ping Li; Xiao Zhang; Zhongyang Lu; Shan Ping Yu; Ling Wei
Journal:  Brain Res       Date:  2011-11-19       Impact factor: 3.252

Review 2.  Fractones: extracellular matrix niche controlling stem cell fate and growth factor activity in the brain in health and disease.

Authors:  Frederic Mercier
Journal:  Cell Mol Life Sci       Date:  2016-07-30       Impact factor: 9.261

3.  Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion.

Authors:  Madhuchhanda Roy; Jane Reiland; Brian P Murry; Vladimir Chouljenko; Konstantin G Kousoulas; Dario Marchetti
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

Review 4.  Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology.

Authors:  Hayamitsu Adachi; Koichi Nakae; Shuichi Sakamoto; Chisato Nosaka; Sonoko Atsumi; Masabumi Shibuya; Nobuaki Higashi; Motowo Nakajima; Tatsuro Irimura; Yoshio Nishimura
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

5.  Prophylactic Antiheparanase Activity by PG545 Is Antiviral In Vitro and Protects against Ross River Virus Disease in Mice.

Authors:  Aroon Supramaniam; Xiang Liu; Vito Ferro; Lara J Herrero
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

6.  Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP.

Authors:  Olga Ostrovsky; Avichai Shimoni; Polina Baryakh; Yan Morgulis; Margarita Mayorov; Katia Beider; Anna Shteingauz; Neta Ilan; Israel Vlodavsky; Arnon Nagler
Journal:  J Leukoc Biol       Date:  2013-12-06       Impact factor: 4.962

Review 7.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

8.  Vascular endothelial growth factor c/vascular endothelial growth factor receptor 3 signaling regulates chemokine gradients and lymphocyte migration from tissues to lymphatics.

Authors:  Daiki Iwami; C Colin Brinkman; Jonathan S Bromberg
Journal:  Transplantation       Date:  2015-04       Impact factor: 4.939

Review 9.  Heparanase: a target for drug discovery in cancer and inflammation.

Authors:  E A McKenzie
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

10.  Dissociation between mature phenotype and impaired transmigration in dendritic cells from heparanase-deficient mice.

Authors:  Sandrine Benhamron; Inna Reiner; Eyal Zcharia; Mizhir Atallah; Amir Grau; Israel Vlodavsky; Dror Mevorach
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.